New research license from Israel will help us understand cannabinoid formulations as they’re related to cancer patients.
Cannabics Pharmaceuticals Inc., the United States based publicly traded company, announced just last week that they have received a new research license from the Israeli Ministry of Health. This license is for the characterization of anti-tumor activity of cannabinoids. Cannabics dedicates their resources to the development of personalized anti-cancer and palliative treatments. The talented team at Cannabics commonly uses technology tools to further our understanding of diagnostics as they’re related to cancer patients who medicate with cannabinoid formulations.
The Research and Development (R&D) segment of Cannabics is licensed for scientific and clinical research in Israel. Their main focus is to understand and harness the therapeutic aspects of naturally occurring cannabinoid formulations, mostly in cancer patients. Cannabinoid formulations are pharmacological combinations utilizing the compounds found in cannabis. They individually tailor natural therapies for these patients by using advanced screening systems and personalized bioinformatics tools. These efforts will be helped along by their newest license from the Ministry.
Their plan with this new license will fine tune a synergy between HTS (High Throughput Screening), CTCs (Circulating Tumor Cells), Drug Efficacy, and Genomic Data to provide therapists and their patients with personalized supportive data for their treatment. This data will hopefully allow them to provide both patients and practitioners with the diagnostic tools as they’re relevant to cannabinoid medicine.
Aside from this new license, Cannabics is working on projects that deliver precise data regarding individual patient treatment for cancer and any of its side effects. They are currently engaged in one clinical study with their R&D team in Israel. This study is using Cannabics capsules as a treatment for improving cancer-related Cancer Anorexia-Cachexia Syndrome (CACS). This research, and the two other preclinical trials they’re running, all have a common theme of using technology as a means to further our understanding of treating cancer patients with medicinal cannabis.